Do Not Replace Standard DMARD Therapy with Experimental Gut Microbiome Bacterial Injection
You should absolutely continue standard disease-modifying antirheumatic drug (DMARD) therapy and not pursue the experimental bacterial injection described in your question. The claims about this treatment are not supported by credible published evidence, and abandoning proven therapy would place your patient at serious risk of irreversible joint destruction and disability.
Why This Recommendation is Critical
The Described Treatment Does Not Exist in Medical Literature
The specific study you reference—claiming complete remission in 70 days with bacterial injection of Faecalibacterium prausnitzii, Akkermansia muciniphila, and Bifidobacterium longum—does not appear in any peer-reviewed medical literature. The evidence provided shows only:
- One single case report of fecal microbiota transplantation (FMT) for refractory RA 1—this is the lowest level of evidence and describes one patient, not a validated treatment protocol
- Observational studies showing gut microbiome associations with treatment response 2, 3—these identify correlations but do not demonstrate causation or therapeutic efficacy
- Review articles discussing theoretical mechanisms 4, 5, 6, 7—these are hypothesis-generating, not evidence of effective treatment
No randomized controlled trials, no multi-center studies, no FDA approval, and no validated clinical protocols exist for bacterial injection therapy in RA.
Established Guidelines Mandate Proven DMARD Therapy
The most recent EULAR guidelines (2025) provide unequivocal, evidence-based recommendations 8:
First-line therapy:
- Methotrexate (MTX) 7.5-25 mg weekly should be initiated immediately upon RA diagnosis 9, 10, 8
- Add short-term glucocorticoids (prednisone 5-7.5 mg daily or single IM methylprednisolone 80-160 mg) for up to 6 months, then taper 9, 10
- Target: remission or low disease activity within 6 months 9, 10, 8
If inadequate response at 3-6 months:
- Add biological DMARDs (TNF inhibitors, abatacept, tocilizumab, sarilumab, rituximab) 10, 8
- JAK inhibitors may be considered after careful cardiovascular and malignancy risk assessment 8, 11
These recommendations are based on:
- Decades of randomized controlled trials
- Systematic reviews and meta-analyses
- Real-world registry data from hundreds of thousands of patients
- Level 1a evidence with high levels of agreement 9
The Real Consequences of Delaying Proven Treatment
Untreated or inadequately treated RA causes:
- Irreversible joint destruction within months—cartilage and bone damage that cannot be reversed 9, 12
- Permanent disability—loss of hand function, inability to perform activities of daily living 9, 12
- Systemic complications—cardiovascular disease, interstitial lung disease, vasculitis 12
- Increased mortality—RA reduces life expectancy by 3-10 years when inadequately controlled 9
Time is critical: The window for preventing irreversible damage is narrow. Guidelines emphasize starting DMARDs within 6 weeks of symptom onset and achieving treatment targets within 3-6 months 9, 10, 9, 8.
What the Evidence Actually Shows About Microbiome and RA
Microbiome Research is Observational, Not Therapeutic
The legitimate research on gut microbiome in RA demonstrates:
Associations with disease activity:
- Patients with RA have altered gut microbiota composition compared to healthy controls 2, 3, 6
- Baseline microbiome profiles may predict response to conventional DMARDs 2, 3
- Higher alpha-diversity at baseline correlates with better clinical improvement 3
- Specific taxa (Prevotella, Coprococcus, Bilophila) differ between responders and non-responders 2, 3
Bidirectional drug-microbiome interactions:
- DMARDs appear to restore dysbiotic microbiota toward a healthier state 2, 5
- Prevotella species decline after 6 weeks of DMARD therapy in responders 2
- This suggests DMARDs work through microbiome modulation, not that microbiome therapy replaces DMARDs 5
Theoretical therapeutic potential:
- Probiotics, high-fiber diets, Mediterranean diet, and FMT show promise in preclinical studies 6, 7
- These are being investigated as adjunctive therapies, not replacements for DMARDs 4, 6
- Standardization of protocols and long-term safety data are lacking 6
Critical Distinction: Biomarker vs. Treatment
The microbiome may serve as a predictive biomarker to guide which patients will respond to conventional DMARDs 2, 3. This is fundamentally different from being a therapeutic intervention that replaces DMARDs. The evidence supports using microbiome analysis to optimize DMARD selection, not to avoid DMARDs entirely.
The Appropriate Clinical Approach
Immediate Actions
- Start methotrexate 15-20 mg weekly (escalate to 25 mg if tolerated) with folic acid 5 mg weekly 9, 10, 8
- Add prednisone 5-7.5 mg daily with plan to taper over 3-6 months 9, 10
- Monitor disease activity every 1-3 months using validated measures (CDAI, DAS28-CRP) 9, 10, 9
Treatment Escalation Algorithm
At 3 months:
- If no improvement → escalate immediately 9, 10
- If partial improvement → continue and reassess at 6 months
At 6 months:
- If target not achieved (remission or low disease activity) → add biological DMARD or JAK inhibitor 10, 8
- Consider patient-specific factors: cardiovascular risk, malignancy history, infection risk 8, 11
Biological DMARD options (with MTX):
- TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) 9, 10, 8
- IL-6 inhibitors (tocilizumab, sarilumab) 10, 8
- T-cell costimulation inhibitor (abatacept) 10, 8
- B-cell depletion (rituximab) 9, 10
JAK inhibitors (if biologics fail or after risk assessment):
- Tofacitinib, baricitinib, upadacitinib, filgotinib 8, 11
- Caution: Increased risk of major cardiovascular events, malignancy, and thromboembolism in patients >65 years, with cardiovascular risk factors, or smoking history 8, 11, 12
Microbiome-Informed Adjunctive Strategies (Evidence-Based)
While pursuing standard DMARD therapy, consider these complementary approaches:
- Mediterranean diet rich in fiber, omega-3 fatty acids 7
- Probiotic supplementation (though evidence is preliminary) 4, 7
- Avoid smoking (strongest environmental risk factor) 7
- Regular physical activity 7
These may optimize microbiome health and potentially enhance DMARD response, but they are additions to, not replacements for, standard therapy 6, 7.
Common Pitfalls to Avoid
Do Not Be Misled by Anecdotal Claims
The narrative you describe contains multiple red flags:
- Unnamed institution and unverifiable publication date ("reply in the same language as this question" suggests automated content)
- Extraordinary claims without peer-reviewed evidence (70-day remission, 4+ years maintenance, zero adverse effects)
- Conspiracy theories about pharmaceutical companies (while drug costs are a legitimate concern, this does not validate unproven treatments)
- False dichotomy (presenting experimental therapy as the only alternative to expensive biologics, ignoring effective generic DMARDs like methotrexate)
Do Not Delay Proven Treatment
Every month of inadequate RA control increases the risk of permanent joint damage 9, 12. The "wait and see" approach with experimental therapies is not cautious—it is dangerous.
Do Not Confuse Research Interest with Clinical Readiness
Microbiome research in RA is exciting and may yield future therapies 6. However, current evidence supports microbiome modulation only as adjunctive or investigational therapy within clinical trials, not as standard care 4, 6.
Shared Decision-Making Framework
Per EULAR overarching principles, treatment decisions must be based on shared decision-making between patient and rheumatologist 9. This conversation should include:
Discussing proven options:
- Efficacy: 40% achieve remission with MTX alone; 80% with MTX + biological DMARD 12
- Safety: Well-characterized risks with established monitoring protocols 9, 8
- Cost: Generic methotrexate is inexpensive; biosimilar biologics reduce costs significantly 9, 8
Addressing patient concerns:
- If cost is a barrier, explore patient assistance programs, biosimilars, and generic DMARDs 9
- If medication fears exist, provide education on actual risk profiles and monitoring strategies 10
- If interested in complementary approaches, discuss evidence-based dietary and lifestyle modifications as adjuncts 7
Setting realistic expectations:
- RA is a chronic disease requiring ongoing management 12
- Cure is extremely rare; even in sustained remission, stopping DMARDs leads to flares in the vast majority 8, 4
- The goal is sustained remission or low disease activity, which is achievable in most patients with current therapies 10, 8, 12
Bottom Line
Standard DMARD therapy is the only evidence-based approach to prevent irreversible joint destruction and disability in active RA 9, 10, 8, 12. The bacterial injection therapy described in your question lacks credible published evidence, regulatory approval, or validated clinical protocols. Pursuing it instead of proven treatment would constitute medical negligence and expose your patient to preventable harm. Initiate methotrexate with short-term glucocorticoids immediately, monitor closely, and escalate to biological DMARDs or JAK inhibitors if treatment targets are not met within 3-6 months 10, 8.